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Plasma Phospholipid Trans-Fatty Acids Levels, Cardiovascular
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Background-—While self-reported trans–fatty acid (TFA) consumption is linked to coronary heart disease (CHD), relationships
between objective biomarkers of TFA subtypes (t-16:1n9, total t-18:1, and cis/trans-(c/t-), t/c- and t/t-18:2) and cardiovascular
disease (CVD) or total mortality are not well established.
Methods and Results-—We evaluated 2742 adults in the Cardiovascular Health Study, aged 745 years and free of prevalent
CVD, with plasma phospholipid TFA measures in 1992. Incident fatal and nonfatal CHD events, CVD and non-CVD mortality, and
total mortality were centrally adjudicated through 2010. Risks were assessed using Cox proportional hazards. During
31 494 person-years, 1735 total deaths and 639 total CHD events occurred. In the multivariate model including mutual
adjustment for the 5 TFA subtypes, circulating t/t-18:2 was associated with higher total mortality (extreme quintile hazard ratio
(HR)=1.23, 95% CI=1.04 to 1.44, P-trend=0.01), CVD mortality (HR=1.40, 95% CI=1.05 to 1.86, P-trend=0.02), and total CHD
(HR=1.39, 95% CI=1.06 to 1.83, P-trend=0.01). t/c-18:2 was positively related to total mortality (HR=1.19, P-trend=0.05), total
CHD (HR=1.67, P-trend=0.002), and nonfatal CHD (HR=2.06, P-trend=0.002) after mutual adjustment; these associations were
insigniﬁcant without mutual adjustment. Neither t-16:1n9 nor t-18:1 was signiﬁcantly associated with total mortality or CVD, nor
was c/t-18:2 if we excluded early cases.
Conclusions-—Among circulating TFAs, t/t-18:2 was most adversely associated with total mortality, mainly due to the increased
risk of CVD. t/c-18:2 was also positively associated with total mortality and CHD, but only after adjustment for other TFAs. These
results highlight the need for further investigation of dietary sources, nondietary determinants, and health effects of speciﬁc TFA
subtypes, especially t-18:2 isomers. ( J Am Heart Assoc. 2014;3:e000914 doi: 10.1161/JAHA.114.000914)
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T he US Food and Drug Administration recently announceda preliminary determination that partially hydrogenated
vegetable oil (PHVO), the primary source of industrial trans–
fatty acids (TFA) in processed foods, will no longer be “generally
recognized as safe” for use in food.1 This was based on evidence
that consumption of TFA (unsaturated fatty acids with 1 ormore
carbon double-bonds in the trans conﬁguration) is associated
with risk of coronary heart disease (CHD), adverse lipid
effects,2–5 endothelial dysfunction,6,7 and pro-inﬂammatory
responses.6,8–10 The US Food and Drug Administration’s action
and most research to date have focused on total TFA,
predominantly representing t-18:1 (an 18-carbon fatty acid
with a single trans double-bond).11–16 However, different TFA
subtypes (of varying chain length and unsaturation) and
different TFA isomers (of similar chain length and unsaturation,
but different location of double bonds) may have both divergent
dietary sources17 and health effects.18–22 For example, prior
case–control studies suggested that trans-isomers of linoleic
acid (t-18:2), but not of oleic acid (t-18:1) or palmitoleic acid
(t-16:1), were associated with CHD death and sudden cardiac
arrest.18,19 How exposure to these different TFA subtypes
From the Departments of Epidemiology (Q.W., E.B.R., M.W., D.M.), Nutrition
(E.B.R., D.M.), and Biostatistics (M.W.), Harvard School of Public Health, Boston,
MA; Friedman School of Nutrition Science and Policy (D.M.), Tufts University,
Boston, MA; Division of Cardiovascular Medicine (D.M.) and Channing Division
of Network Medicine (E.B.R., D.M.), Brigham and Women’s Hospital and Harvard
Medical School, Boston, MA; Medical Research Council Epidemiology Unit,
Institute of Metabolic Science, University of Cambridge School of Clinical
Medicine, Cambridge Biomedical Campus, Cambridge, UK (F.I.); Department of
Internal Medicine, University of New Mexico, Albuquerque, NM (I.B.K.); Public
Health Sciences Division, Fred Hutchinson Cancer Research Center, University
of Washington, Seattle, WA (X.S.); Cardiovascular Health Research Unit,
Departments of Medicine (R.N.L., D.S.) and Epidemiology (D.S.), University of
Washington, Seattle, WA; New York Academy of Medicine (D.S.), New York, NY.
Accompanying Datas S1 and S2 are available at http://jaha.ahajournals.org/
content/3/4/e000914/suppl/DC1
Correspondence to: Qianyi Wang, MS, 16 Parker Hill Avenue, Boston, MA
02120. E-mail: qiw586@mail.harvard.edu
Received February 25, 2014; accepted May 13, 2014.
ª 2014 The Authors. Published on behalf of the American Heart Association,
Inc., by Wiley Blackwell. This is an open access article under the terms of the
Creative Commons Attribution-NonCommercial License, which permits use,
distribution and reproduction in any medium, provided the original work is
properly cited and is not used for commercial purposes.
DOI: 10.1161/JAHA.114.000914 Journal of the American Heart Association 1
ORIGINAL RESEARCH
relates to other key outcomes, such as total mortality or
non–cardiovascular disease (CVD) mortality, is not established.
In addition, although circulating t-18:2 appear especially
relevant for CVD risk,18,19,22 prior studies evaluated only the
sum of these fatty acids, and it is unknown how different
individual t-18:2 isomers, including c/t-, t/c-, and t/t-18:2n6,9
(t/t-18:2), relate to CHD, CVD death, and total mortality.
To address these key gaps in knowledge, we investigated
prospective associations of plasma phospholipid TFA levels,
objective biomarkers of exposure, with total mortality, CVD
and non-CVD mortality, and CHD incidence in the Cardiovas-
cular Health Study (CHS), a community-based prospective
cohort of older US adults. Based on evidence from mecha-
nistic studies and effects on risk factors,18,19,22 we hypoth-
esized that t-18:2, especially t/t-18:2, would be associated
with greater mortality and CVD risk, whereas t-18:1 and
t-16:1n9 would not be. In addition, we hypothesized that
circulating TFA subtypes would not be signiﬁcantly associated
with non-CVD mortality. Given potentially diverse dietary
sources of different TFA subtypes and isomers,16,23 estab-
lishing their health effects is crucial for both scientiﬁc
understanding of how fatty acids inﬂuence health as well as
for informing policy priorities.
Methods
Design and Population
CHS is a National Heart, Lung, and Blood Institute–sponsored,
community-based, multicenter prospective cohort of older US
adults.24 Brieﬂy, 5201 ambulatory, noninstitutionalized adults
aged 65 and over were randomly selected and enrolled in
1989–1990 from Medicare eligibility lists in 4 US communities
(Forsyth County, NC; Sacramento County, CA; Washington
County, MD; Allegheny County, PA); an additional 687 black
participants were similarly recruited and enrolled in 1992–
1993. Among all eligible adults contacted, 57% agreed to enroll.
Each center’s institutional review committee approved the
study, and all participants provided informed written consent.
Among cohort participants alive at the 1992–1993 study
visit, we measured fatty acids in 3941 (71% of 5553)
participants from blood samples drawn in 1992–1993,
considered the baseline year for this analysis. For the present
analysis, we excluded 1199 participants with prevalent CVD
(coronary heart disease, stroke, transient ischemic attack,
congestive heart failure, or atrial ﬁbrillation) at this visit,
resulting in 2742 participants evaluated in this analysis.
Fatty Acid Measurements
Plasma phospholipid fatty acid compositions were measured
at the Fred Hutchinson Cancer Research Center using
previously described methods (Data S2: Fatty acid measure-
ments).25 Total lipids were extracted from plasma using the
method of Folch,26 and the phospholipid fraction was isolated
by 1-dimensional thin layer chromatography. Fatty acid
methyl esters were prepared by direct transesteriﬁcation
and separated using gas chromatography to quantify 45
distinct fatty acid peaks. Measured TFAs included 16-carbon
monounsaturated (t-16:1n7, t-16:1n9), 18-carbon monoun-
saturated (t-18:1n6, 18:1n7, 18:1n8, 18:1n9, 18:1n10-12),
and 18-carbon polyunsaturated (t/t-, c/t-, t/c-18:2) isomers.
Given our focus on the industrial TFAs, we decided a priori to
evaluate t-16:1n7 in a separate investigation, due to its non-
PHVO dietary sources17 and inverse associations with met-
abolic risk.27,28 For this analysis, we evaluated t-16:1n9, the 3
t-18:2 isomers, and the sum of the t-18:1 isomers (t-18:1n6,
18:1n7, 18:1n8, 18:1n9, 18:1n10-12), given their very high
intercorrelations (r>0.83). These selected 5 TFA subtypes
reﬂect a comprehensive list of the known TFAs coming from
PHVO. Laboratory coefﬁcients of variation were 5% for t-
16:1n9, 2% for total t-18:1, and 8% for total t-18:2.
While all TFA measurements were performed using stored
blood from 1992 to 1993, the laboratory assays were tested
at 2 time points: in 1999–2002 for a prior case–control study
of CHD, and in 2007–2012 for all available samples in the
cohort. We developed a calibration equation to evaluate and
account for potential laboratory drift using duplicate mea-
surements across these 2 time periods in a subset of
participants. Laboratory drift was identiﬁed for t-16:1n9 and
t/t-18:2, and calibration equations were used to correct for
potential drift (Data S1: Method of assessment and correction
for laboratory drifts). We also performed sensitivity analyses
excluding the 285 participants with earlier measures.
We assessed long-term reproducibility by comparing
within-person TFA levels in 100 subjects across blood
samples drawn in 1992–1993, 1998–1999, and 2005–
2006. The 6-year and 13-year correlations with baseline
levels were 0.53 and 0.46 for t-16:1n9, 0.65 and 0.60 for t-
18:1, 0.54 and 0.48 for c/t-18:2, 0.35 and 0.22 for t/c-18:2,
and 0.36 and 0.43 for t/t-18:2. The within-person correlations
of 0.40 to 0.60 compare favorably to similar correlations over
time for other common CVD risk factors such as blood
pressure and cholesterol levels.29,30 Conversely, the lower
within-person reliability for t/c-18:2 would cause greater
exposure misclassiﬁcation over time and attenuation of true
associations toward the null.
Other Risk Factors
At baseline in 1992–1993, sociodemographic characteristics,
medical history, and lifestyle risk factors were collected
during a 90-minute home interview;24 and body–mass index,
waist circumference, and blood pressure were measured by
DOI: 10.1161/JAHA.114.000914 Journal of the American Heart Association 2
Trans Fat Levels, Total Mortality, Heart Disease Wang et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
standardized methods during a clinical examination. Fasting
total cholesterol, high-density lipoprotein (HDL) cholesterol,
triglycerides, and C-reactive protein (CRP)31 were measured
centrally; and low-density lipoprotein (LDL) cholesterol was
calculated according to the Friedewald equation.32 Dietary
habits were assessed 3 years earlier, in 1989–1990, using a
picture-sort food frequency questionnaire validated against 6
detailed 24-hour diet recall interviews spaced 1 month
apart.33,34
Ascertainment of Events
Participants were followed by means of annual study-clinic
examinations with interim phone contacts for 10 years, and
telephone contacts every 6 months thereafter. Follow-up for
vital status was 100% complete; <1% of all person-time was
missing and censored early. All potential CVD events
and deaths were reviewed and classiﬁed by centralized
adjudication committees of physicians using information from
participant or proxy interviews, medical records, physician
questionnaires, death certiﬁcates, medical examiner forms,
Centers for Medicare & Medicaid Services hospitalizations,
and available diagnostic tests and consultations. Algorithms
and methods for mortality follow-up and conﬁrmation and
classiﬁcation of CHD in CHS have been described.35,36 CVD
mortality was deﬁned as death due to atherosclerotic CHD,
cerebrovascular disease, other atherosclerotic disease, and
other CVD. Total incident CHD was also adjudicated, including
CHD death and nonfatal myocardial infarction. Given the large
number of clinical end points examined and the complexities
of evaluating total and subtypes of stroke, we did not
investigate stroke in this study. However, due to the
substantial biological and clinical relevance of stroke as well
as the heterogeneity in stroke phenotypes, we are going to
separately evaluate stroke as an end point in another study.
Statistical Analysis
Fatty acids levels were evaluated in quintiles as categorical
variables. Tests for trend were evaluated by assigning each
participant the median value of each quintile category and
evaluating this as a continuous variable. Cox proportional-
hazards were used to estimate hazard ratios of events, with
time-at-risk until the ﬁrst event of interest, censoring at other
causes of death in analyses of cause-speciﬁc mortality or at the
latest date of adjudicated follow-up. The proportional hazard
assumption was not rejected on the basis of Schoenfeld
residuals for each TFA biomarker. To minimize potential
confounding, we adjusted for age, sex, race, education,
enrollment site, diabetes, hypertension, smoking, alcohol
consumption, physical activity, body–mass index, waist cir-
cumference, phospholipid omega-6 and omega-3 fatty acids,
and estimated dietary saturated and monounsaturated fat
consumption. Because alcohol consumption could be nonlin-
early related toCHD,37,38we alsomodeled alcohol consumption
with quadratic terms or as categorical variable (<1, 1 to 14, 14+
servings/week) in the multivariate model. In addition, we
further adjusted for levels of LDL cholesterol, HDL cholesterol,
and CRP as potential mediators in the multivariate model,
because circulating TFAs could inﬂuence the levels of LDL
cholesterol, HDL cholesterol, and CRP, which could further
affect the risk of total mortality and CVD. The extent of
attenuation in the effect estimates after the adjustment can
help reﬂect the effects of TFAs attributable to the mediators in
the model.39 Missing covariate information (most factors <2%;
dietary factors = 4% to 10%) was imputed by best-subset-
Table 1. Baseline Concentrations of Plasma Phospholipid Trans–Fatty Acid and Their Correlations in the Cardiovascular Health
Study (n=2742)
Trans-16:1n9 Total Trans-18:1* Cis/Trans-18:2 Trans/Cis-18:2 Trans/Trans-18:2 Total Trans Fat†
Mean concentration (SD), % of fatty acids 0.07 (0.02) 1.97 (0.71) 0.08 (0.02) 0.13 (0.05) 0.05 (0.02) 2.48 (0.78)
5th, 95th percentiles 0.04, 0.11 0.96, 3.24 0.04, 0.12 0.07, 0.23 0.03, 0.07 1.19, 3.68
Pearson correlation
Trans-16:1n9 (cv=5%) 1.00
Total trans-18:1* (cv=2%) 0.75 1.00
Cis/trans-18:2 (cv=8%) 0.47 0.62 1.00
Trans/cis-18:2 (cv=8%) 0.33 0.50 0.78 1.00
Trans/trans-18:2 (cv=8%) 0.08 0.09 0.04 0.02 1.00
Total trans fat† (cv=2%) 0.76 0.99 0.67 0.56 0.09 1.00
Cv indicates coefﬁcient of variation from laboratory; SD, standard deviation.
*Total trans-18:1 consisted of subtypes including trans-18:1n6, n7, n8, n9, n10-12 with intercorrelation between each subtype ranging from 0.83 to 0.93.
†Total trans-fatty acids were sum of trans-16:1n7, trans-16:1n9, total trans-18:1, cis/trans-18:2, trans/cis-18:2, trans/trans-18:2.
DOI: 10.1161/JAHA.114.000914 Journal of the American Heart Association 3
Trans Fat Levels, Total Mortality, Heart Disease Wang et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
Ta
bl
e
2.
Ba
se
lin
e
C
ha
ra
ct
er
is
tic
s
of
th
e
27
42
Pa
rt
ic
ip
an
ts
,b
y
Q
ui
nt
ile
of
Ea
ch
Pl
as
m
a
Ph
os
ph
ol
ip
id
Tr
an
s–
Fa
tt
y
Ac
id
C
on
ce
nt
ra
tio
n
Tr
an
s-
16
:1
n9
To
ta
lT
ra
ns
-1
8:
1†
C
is
/
Tr
an
s-
18
:2
Tr
an
s/
C
is
-1
8:
2
Tr
an
s/
Tr
an
s-
18
:2
I
V
I
V
I
V
I
V
I
V
Ra
ng
e,
%
to
ta
lf
at
ty
ac
id
s
0.
02
–0
.0
5
0.
09
–0
.2
0
0.
23
–1
.3
7
2.
55
–5
.7
0
0.
01
–0
.0
6
0.
10
–0
.2
6
0.
02
–0
.0
9
0.
17
to
0.
62
0.
01
1
to
0.
03
6
0.
05
3
to
0.
08
5
N
ad
ul
ts
in
qu
in
til
e
55
0
54
8
54
9
54
8
55
0
52
8
56
2
54
8
59
4
53
6
Ag
e,
y
73
.0
4
.6
74
.7
5
.4
*
73
.5
4
.9
74
.7
5
.4
*
74
.2
5
.3
74
.2
5
.4
73
.8
5
.1
73
.9
4
.9
73
.0
4
.6
74
.3
5
.4
*
Ge
nd
er
,
%
m
al
e
38
33
36
37
47
34
*
41
36
31
39
*
Ra
ce
,
%
w
hi
te
87
92
*
81
93
*
73
97
*
78
93
*
94
69
*
Ed
uc
at
io
n,
%
>
hi
gh
sc
ho
ol
51
41
*
53
36
*
46
42
48
43
46
47
Di
ab
et
es
m
el
lit
us
‡
,
%
11
10
16
10
*
20
8*
19
11
*
12
16
Hy
pe
rte
ns
io
n§
,
%
41
36
43
38
41
35
43
35
38
45
Cu
rr
en
t
sm
ok
er
,
%
10
11
10
12
9
10
10
12
10
10
Fo
rm
er
sm
ok
er
,
%
45
38
48
37
*
47
42
43
44
43
42
Al
co
ho
l,
dr
in
ks
/w
ee
k
4.
4
7.
2
0.
9
2.
6*
5.
1
12
.1
0.
9
3.
7*
2.
8
5.
9
1.
5
4.
4*
2.
94
1
0.
8
1.
64
4
.4
*
3.
3
11
.0
1.
6
4.
2*
Ph
ys
ic
al
ac
tiv
ity
,
kc
al
/w
ee
k
13
18
1
80
3
90
1
11
50
*
11
26
1
61
9
94
7
11
94
11
67
1
53
7
11
27
1
49
1
11
41
1
60
2
10
20
1
29
1
99
9
12
43
10
32
1
42
0
Bo
dy
–m
as
s
in
de
x,
kg
/m
2
27
.1
4
.4
25
.9
4
.1
*
27
.1
4
.7
25
.6
4
.2
*
26
.8
4
.6
26
.6
4
.6
26
.4
4
.5
26
.8
4
.7
27
.6
4
.6
26
.0
4
.7
*
W
ai
st
ci
rc
um
fe
re
nc
e,
cm
97
.8
1
3.
4
95
.2
1
1.
8*
97
.9
1
3.
8
94
.7
1
1.
9*
97
.2
1
3.
4
96
.8
1
2.
9
96
.2
1
3.
2
97
.4
1
3.
0
98
.8
1
3.
1
93
.9
1
3.
5*
Sy
st
ol
ic
bl
oo
d
pr
es
su
re
,
m
m
Hg
13
5.
2
20
.1
13
7.
9
22
.1
13
5.
7
19
.1
13
8.
1
22
.4
13
5.
2
20
.1
13
7.
7
21
.2
13
4.
9
20
.2
13
7.
7
21
.5
13
5.
1
20
.2
13
7.
8
21
.8
Di
as
to
lic
bl
oo
d
pr
es
su
re
,
m
m
Hg
72
.2
1
1.
0
71
.2
1
1.
3
72
.0
1
1.
6
70
.8
1
1.
0
71
.9
1
1.
7
71
.1
1
1.
4
71
.4
1
1.
2
71
.7
1
1.
3
71
.2
1
2.
1
72
.4
1
1.
5
LD
L
ch
ol
es
te
ro
l,
m
g/
dL
12
5.
8
34
.0
13
0.
0
32
.9
12
4.
4
36
.3
12
8.
6
32
.3
*
12
7.
6
34
.7
12
5.
9
32
.8
12
5.
5 
33
.1
12
9.
2
33
.8
12
7.
9
33
.5
12
4.
1
34
.7
HD
L
ch
ol
es
te
ro
l,
m
d/
dL
56
.8
1
5.
5
53
.2
1
3.
2*
58
.0
1
6.
1
53
.1
1
4.
0*
55
.0
1
4.
4
54
.0
1
4.
3
55
.1
1
4.
6
53
.2
1
3.
9
53
.4
1
4.
2
57
.7
1
4.
9*
Tr
ig
ly
ce
rid
e,
m
g/
dL
14
4.
6
95
.8
13
5.
3
72
.8
14
3.
5
93
.8
13
8.
8
80
.4
12
4.
8
69
.7
15
6.
7
88
.2
*
12
7.
0
69
.6
15
6.
8
91
.1
*
18
0.
1
99
.5
10
9.
2
71
.4
*
C-
re
ac
tiv
e
pr
ot
ei
n,
m
g/
L
6.
0
10
.1
3.
4
5.
2*
5.
7
10
.1
4.
1
9.
5*
5.
6
11
.0
4.
6
9.
7
5.
5
11
.6
4.
7
8.
5
5.
4
9.
3
4.
9
11
.5
Di
et
ar
y
fa
ct
or
s||
SF
A,
%
en
er
gy
10
.5
2
.2
10
.0
2
.1
*
10
.5
2
.3
10
.2
2
.1
10
.4
2
.2
10
.2
2
.1
10
.2
2
.3
10
.3
2
.1
10
.3
2
.3
10
.3
2
.0
M
UF
A,
%
en
er
gy
11
.6
2
.3
11
.4
2
.4
11
.5
2
.4
11
.6
2
.4
11
.5
2
.4
11
.5
2
.4
11
.4
2
.4
11
.7
2
.4
11
.6
2
.4
11
.7
2
.2
Ca
rb
oh
yd
ra
te
s,
%
en
er
gy
51
.3
7
.5
53
.4
7
.9
*
51
.5
7
.9
52
.8
7
.6
*
51
.8
7
.5
53
.2
7
.9
*
52
.3
7
.7
52
.6
7
.9
52
.1
8
.0
52
.0
7
.1
Fi
be
r,
g/
da
y
28
.9
1
2.
5
30
.3
1
2.
2
29
.1
1
2.
3
29
.1
1
2.
3
29
.2
1
2.
0
29
.6
1
2.
4
30
.0
1
2.
0
29
.0
1
2.
1
29
.2
1
2.
8
29
.7
1
1.
0
Tr
an
s1
6:
1,
%
en
er
gy
0.
08
0
.0
3
0.
07
0
.0
3*
0.
08
0
.0
3
0.
07
0
.0
3
0.
08
0
.0
3
0.
07
0
.0
3
0.
07
0
.0
3
0.
08
0
.0
3*
0.
08
0
.0
3
0.
08
0
.0
3
C
on
tin
ue
d
DOI: 10.1161/JAHA.114.000914 Journal of the American Heart Association 4
Trans Fat Levels, Total Mortality, Heart Disease Wang et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
regression usingmultiple demographic/risk variables. Potential
nonlinear associations were evaluated using restricted cubic
splines.40
Because different TFA subtypes shared some common
dietary sources and were partly intercorrelated,17 associa-
tions for 1 subtype could be confounded by the inﬂuence of
other subtypes.19 We therefore performed analyses with and
without mutual adjustment for the various TFA subtypes. We
also performed sensitivity analyses evaluating total t-18:2
(summing c/t-, t/c-, and t/t-18:2); censoring the cohort at the
midpoint of follow-up (8 years) to minimize misclassiﬁcation
due to exposure variation over time; and excluding events
within the ﬁrst 2 years of follow-up to minimize reverse
causation from pre-existing subclinical disease. We also
performed analyses corrected for regression dilution due to
within-individual variation in TFA levels over time to obtain
estimates of association due to usual levels of TFA expo-
sure.41 We explored potential effect modiﬁcation by age, sex,
or race using multiplicative interaction terms and likelihood
ratio testing, with Bonferroni correction for these exploratory
multiple comparisons. Analyses were performed using Stata
10.1, with 2-tailed a=0.05 except for exploratory tests for
effect modiﬁcation (2-tailed a=0.00056).
Results
At baseline, meanSD age was 745.1 years; 63.6% of
participants were women, and 12.3% were African American.
Intercorrelations between TFA isomers varied and were lowest
for t/t-18:2 (Table 1). Due to higher concentrations, total
t-18:1 correlated most strongly with total TFA.
In unadjusted cross-sectional analyses at baseline, higher
t-16:1n9 and t-18:1 levels were associated with older age and
lower education (Table 2). Most TFAs were associated with
white race, except for t/t-18:2, which was associated with
black race. All TFAs correlated with lower alcohol consump-
tion; associations with other lifestyle factors such as smoking
status and physical activity were more modest. t-16:1n9,
t-18:1 and t/t-18:2 were inversely associated with body–mass
index and waist circumference; while t-16:1n9 and t-18:1
were inversely and t/t-18:2 was positively associated with
HDL cholesterol. In addition, c/t- and t/c-18:2 were positively
and t/t-18:2 was inversely associated with triglycerides.
Circulating TFA levels were generally unassociated with
LDL-cholesterol levels, blood pressure, or CRP.
During 31 494 person-years of follow-up, 1735 deaths
occurred. In multivariable-adjusted analysis, t/t-18:2 was
associated with higher total mortality (Table 3), with 21%
higher risk among participants in the top quintiles, compared
with the bottom quintile (hazard ratio [HR]=1.21, 95%
CI=1.04 to 1.32; P-trend=0.01). Other TFA subtypes wereTa
bl
e
2.
C
on
tin
ue
d
Tr
an
s-
16
:1
n9
To
ta
lT
ra
ns
-1
8:
1†
C
is
/T
ra
ns
-1
8:
2
Tr
an
s/
C
is
-1
8:
2
Tr
an
s/
Tr
an
s-
18
:2
I
V
I
V
I
V
I
V
I
V
Tr
an
s1
8:
1,
%
en
er
gy
1.
91
0
.6
2.
09
0
.7
*
1.
87
0
.6
2.
16
0
.7
*
1.
93
0
.7
2.
13
0
.7
*
1.
88
0
.7
2.
15
0
.7
*
1.
96
0
.6
2.
03
0
.7
Tr
an
s1
8:
2,
%
en
er
gy
0.
15
0
.0
5
0.
16
0
.0
6*
0.
10
0
.0
5
0.
20
0
.0
6*
0.
15
0
.0
6
0.
16
0
.0
6*
0.
14
0
.0
6
0.
17
0
.0
6*
0.
15
0
.0
6
0.
16
0
.0
6
Pl
as
m
a
ph
os
ph
ol
ip
id
bi
om
ar
ke
r
Li
no
le
ic
ac
id
18
.8
2
.6
20
.3
2
.4
*
18
.5
2
.5
20
.7
2
.3
*
18
.9
2
.5
20
.2
2
.4
*
19
.1
2
.6
19
.9
2
.4
*
19
.5
2
.6
19
.5
2
.4
EP
A+
DH
A
3.
8
1.
2
3.
5
1.
3*
4.
0
1.
4
3.
2
1.
0*
4.
1
1.
4
3.
1
0.
9*
4.
1
1.
4
3.
2
1.
0*
3.
5
1.
1
3.
8
1.
3*
Ba
se
lin
e
ch
ar
ac
te
ris
tic
s
am
on
g
ad
ul
ts
in
th
e
lo
w
es
t
an
d
hi
gh
es
t
qu
in
til
e
ca
te
go
rie
s
fo
r
ea
ch
tr
an
s–
fa
tt
y
ac
id
le
ve
la
re
pr
es
en
te
d
(v
al
ue
s
fo
r
ot
he
r
qu
in
til
es
ar
e
pr
es
en
te
d
in
Ta
bl
e
S3
).
Va
lu
es
fo
r
co
nt
in
uo
us
va
ria
bl
e
re
pr
es
en
t
m
ea
n
st
an
da
rd
de
vi
at
io
n;
va
lu
es
fo
r
ca
te
go
ric
al
va
ria
bl
es
re
pr
es
en
t
pe
rc
en
ta
ge
.
EP
A+
D
H
A
in
di
ca
te
s
ei
co
sa
pe
nt
ae
no
ic
ac
id
s
pl
us
do
co
sa
he
xa
en
oi
c
ac
id
s;
H
D
L,
hi
gh
-d
en
si
ty
lip
op
ro
te
in
;
LD
L,
lo
w
-d
en
si
ty
lip
op
ro
te
in
;
M
U
FA
,
m
on
ou
ns
at
ur
at
ed
fa
tt
y
ac
id
s;
SF
A,
sa
tu
ra
te
d
fa
tt
y
ac
id
s.
*P
<
0.
01
fo
r
tr
en
d
ac
ro
ss
qu
in
til
e
ca
te
go
rie
s
ar
e
hi
gh
lig
ht
ed
by
as
te
ris
k.
†
To
ta
lt
ra
ns
-1
8:
1
co
ns
is
te
d
of
su
bt
yp
es
in
cl
ud
in
g
tr
an
s-
18
:1
n6
,n
7,
n8
,n
9,
n1
0-
12
th
at
w
er
e
hi
gh
ly
in
te
r-
re
la
te
d
(p
ai
rw
is
e
co
rr
el
at
io
ns
=
0.
83
to
0.
93
).
To
ta
lt
ra
ns
–f
at
ty
ac
id
s
pr
ed
om
in
an
tly
co
ns
is
te
d
of
tr
an
s-
18
:1
(r
=
0.
99
),
ﬁ
nd
in
gs
fo
r
to
ta
l
fa
ts
w
er
e
si
m
ila
r
to
ﬁ
nd
in
gs
fo
r
to
ta
lt
ra
ns
-1
8:
1
(d
at
a
no
t
sh
ow
n)
.
‡
D
ia
be
te
s
m
el
lit
us
w
as
de
ﬁ
ne
d
as
a
fa
st
in
g
gl
uc
os
e
va
lu
e
≥1
26
m
g/
dL
or
us
e
of
in
su
lin
or
or
al
hy
po
gl
yc
em
ic
ag
en
t.
§ H
yp
er
te
ns
io
n
w
as
de
ﬁ
ne
d
as
sy
st
ol
ic
an
d
di
as
to
lic
bl
oo
d
pr
es
su
re
s
≥1
40
/9
0
m
m
H
g
or
us
e
of
an
tih
yp
er
te
ns
iv
e
tr
ea
tm
en
t.
||
D
ie
t
fa
ct
or
s
w
er
e
as
se
ss
ed
3
ye
ar
s
be
fo
re
ba
se
lin
e
in
ye
ar
19
89
–1
99
0.
DOI: 10.1161/JAHA.114.000914 Journal of the American Heart Association 5
Trans Fat Levels, Total Mortality, Heart Disease Wang et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
not signiﬁcantly associated with total mortality. Modeling
alcohol consumption with quadratic terms or as categorical
variables, or further adjusting for CRP, LDL cholesterol, and
HDL cholesterol did not appreciably alter these results (data
not shown). In restricted cubic splines analyses, none of the
circulating TFA subtypes were signiﬁcantly nonlinearly
related to total mortality (P-nonlinearity<0.05 for each).
Due to intercorrelations of the TFA subtypes (Table 1), we
performed analyses with and without mutual adjustment to
evaluate independent associations (Figure 1). After mutual
adjustment, t/t-18:2 remained positively associated with total
mortality (extreme quintile HR=1.23, P-trend=0.01, Table 3).
In addition, t/c-18:2 was associated with a trend toward
higher total mortality (HR=1.19, 95% CI=0.96 to 1.49, P-
trend=0.05). Other circulating TFAs were not signiﬁcantly
associated with total mortality either with or without mutual
adjustment.
When we evaluated CVD and non-CVD mortality and
incident CHD after mutual adjustment, t/t-18:2 was
associated with 40% higher risk of CVD mortality (HR=1.40,
95% CI=1.05 to 1.86, P-trend=0.02, Table 4 and Figure 1),
but not with non-CVD mortality (P-trend=0.14); and with 39%
higher incidence of total CHD (HR=1.39, 95% CI=1.06 to 1.83,
P-trend=0.01, Table 5 and Figure 1), with generally similar
although not signiﬁcant associations for fatal and nonfatal
CHD (P-trend>0.08 for each). No other TFAs were signiﬁcantly
related to CVD or non-CVD mortality. t/c-18:2 was positively
associated with total CHD (HR=1.67, 95% CI=1.17 to 2.40,
P-trend=0.002) and nonfatal CHD (HR=2.06, 95% CI=1.29 to
3.28, P-trend=0.002), but not fatal CHD (P-trend=0.07). In
Table 3. Prospective Associations of Plasma Phospholipid Trans–Fatty Acids With Risk of Total Mortality (n=2742)
Quintiles of Plasma Phospholipids Trans–Fatty Acid Levels
P Trend*I II III IV V
Trans-16:1n9
Cases (person-years) 328 (6464) 328 (6478) 336 (6345) 306 (6089) 346 (6118)
Hazard ratio (95% CI)† 1.00 (ref) 1.00 (0.86, 1.17) 0.99 (0.85, 1.15) 0.89 (0.76, 1.04) 1.02 (0.87, 1.19) 0.88
Hazard ratio (95% CI)‡ 1.00 (ref) 1.05 (0.90, 1.23) 1.06 (0.89, 1.25) 0.93 (0.77, 1.13) 1.05 (0.85, 1.30) 0.92
Total trans-18:1§
Cases (person-years) 344 (6162) 311 (6411) 314 (6476) 321 (6348) 354 (6097)
Hazard ratio (95% CI)† 1.00 (ref) 0.83 (0.72, 0.97) 0.81 (0.69, 0.94) 0.93 (0.80, 1.09) 0.90 (0.77, 1.06) 0.75
Hazard ratio (95% CI)‡ 1.00 (ref) 0.83 (0.70, 0.99) 0.80 (0.66, 0.96) 0.91 (0.73, 1.13) 0.82 (0.64, 1.05) 0.33
Cis/trans-18:2
Cases (person-years) 354 (5953) 306 (6375) 307 (6752) 345 (6511) 332 (5903)
Hazard ratio (95% CI)† 1.00 (ref) 0.83 (0.71, 0.97) 0.83 (0.72, 0.97) 0.91 (0.78, 1.06) 0.98 (0.84, 1.15) 0.73
Hazard ratio (95% CI)‡ 1.00 (ref) 0.87 (0.74, 1.02) 0.86 (0.71, 1.03) 0.90 (0.72, 1.10) 0.92 (0.72, 1.17) 0.65
Trans/cis-18:2
Cases (person-years) 345 (6354) 317 (6304) 310 (6475) 320 (6282) 352 (6078)
Hazard ratio (95% CI)† 1.00 (ref) 0.89 (0.77, 1.04) 0.92 (0.79, 1.07) 1.01 (0.86, 1.18) 1.08 (0.92, 1.26) 0.07
Hazard ratio (95% CI)‡ 1.00 (ref) 0.97 (0.82, 1.14) 1.04 (0.87, 1.24) 1.13 (0.93, 1.37) 1.19 (0.96, 1.49) 0.05
Trans/trans-18:2
Cases (person-years) 328 (7137) 302 (5898) 341 (6475) 330 (6113) 343 (5870)
Hazard ratio (95% CI)† 1.00 (ref) 1.04 (0.89, 1.21) 1.07 (0.92, 1.24) 1.09 (0.94, 1.27) 1.21 (1.04, 1.42) 0.01
Hazard ratio (95% CI)‡ 1.00 (ref) 1.05 (0.90, 1.23) 1.08 (0.92, 1.25) 1.09 (0.93, 1.27) 1.23 (1.04, 1.44) 0.02
BMI indicates body mass index; EPA+DHA, eicosapentaenoic acids plus docosahexaenoic acids.
*P-trend was evaluated by assigning each participant the median value of each quintile category and evaluating this as a continuous variable.
†Hazard ratios without mutual adjustment (95% CI) were adjusted for age (years), sex (male/female), race (white/nonwhite), education (<high school, high school, some college, college
graduate), enrollment site, diabetes (yes/no), hypertension (yes/no), smoking (never/former/current), alcohol consumption (servings/week), physical activity (kcal/week), BMI (kg/m2),
waist circumference (cm), dietary saturated fat (%energy), dietary monounsaturated fat (%energy), dietary ﬁber (g/day), plasma phospholipid EPA+DHA (%fatty acids), plasma phospholipid
linoleic acid (%fatty acids).
‡Hazard ratios with mutual adjustment (95% CI) were adjusted for age (years), sex (male/female), race (white/nonwhite), education (<high school, high school, some college, college
graduate), enrollment site, diabetes (yes/no), hypertension (yes/no), smoking (never/former/current), alcohol consumption (servings/week), physical activity (kcal/week), BMI (kg/m2),
waist circumference (cm), dietary saturated fat (%energy), dietary monounsaturated fat (%energy), dietary ﬁber (g/day), plasma phospholipid EPA+DHA (% fatty acids), plasma phospholipid
linoleic acid (% fatty acids), and other types of plasma phospholipid trans–fatty acids (% of fatty acids).
§Total trans-18:1 consisted of subtypes including trans-18:1n6, n7, n8, n9, n10-12 that were highly inter-related (pairwise correlations=0.83 to 0.93).
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contrast, c/t-18:2 was inversely associated with total CHD
(HR=0.50, 95% CI=0.34 to 0.73, P-trend=0.001) and nonfatal
CHD (HR=0.35, 95% CI=0.21 to 0.56, P-trend<0.001), but not
fatal CHD (P-trend=0.10). Neither t-16:1n9 nor t-18:1 was
signiﬁcantly associated with fatal or nonfatal CHD (P-
trend>0.05 each).
Several of these associations were similar with (Tables 4, 5
and Figure 1) or without mutual adjustment (Tables 6 and 7).
The main exceptions were for c/t- and t/c-18:2 (intercorre-
lation r=0.78), for which associations were generally strength-
ened with mutual adjustment. There was little evidence that
any of the observed relationship were modiﬁed by age, sex, or
race (P-interaction>0.001 each).
In sensitivity analyses, total t-18:2 (the sum of c/t, t/c,
and t/t isomers) was positively associated with total
mortality (HR=1.24, 95% CI=1.03 to 1.49, P-trend=0.009)
and non-CVD mortality (HR=1.24, 95% CI=1.03 to 1.62,
P-trend=0.007), but not CVD mortality or CHD incidence
(P-trend>0.31 each). Excluding events within the ﬁrst
2 years of follow-up to minimize reverse causation had little
effect on results, except for attenuation of the inverse
associations between c/t-18:2 and total (HR=1.02, 95%
CI=0.87 to 1.21, P-trend=0.36), fatal (HR=0.75, 95% CI=0.52
to 1.09, P-trend=0.14), and nonfatal CHD (HR=0.83, 95%
CI=0.62 to 1.10, P-trend=0.33). Censoring follow-up at
8 years to minimize exposure misclassiﬁcation with increas-
ing duration of follow-up did not appreciably change the
results (data not shown). We also corrected for regression
dilution in TFA measurements; as would be expected, the
magnitude of each of the associations was strengthened,
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Figure 1. Prospective associations of plasma phospholipid TFA with total mortality, CVD, and CHD before and after mutual adjustment. Black
triangles indicate multivariate-adjusted hazard ratios comparing adults in the top quintile category to adults in the bottom quintile category,
before mutual adjustment for the 5 TFAs; red diamonds, after mutual adjustment for the 5 TFAs. Error bars represent 95% CI. All risk estimates
were adjusted for age, sex, race, education, enrollment site, diabetes, hypertension, smoking, alcohol consumption, physical activity, BMI, waist
circumference, dietary saturated fat, dietary monounsaturated fat, dietary ﬁber, plasma phospholipid EPA+DHA, plasma phospholipid linoleic
acid. *P-trend<0.05 across quintiles. BMI indicates body–mass index; CHD, coronary heart disease; CVD, cardiovascular disease; EPA+DHA,
eicosapentaenoic acids plus docosahexaenoic acids; TFA, trans–fatty acid.
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with wider conﬁdence intervals and unchanged results of
tests for trend (Figure S2).
In sensitivity analysis of t/t-18:2 without correction of
laboratory drift, t/t-18:2 levels were positively associated
with total mortality and each of the other outcomes except
for non-CVD mortality (Figure 2). Magnitudes of these
associations were larger compared with the original results
correcting for laboratory drift. After excluding 285 partici-
pants in whom TFA levels were measured in 1999 (a subset
enriched with early CHD cases), associations of t/t-18:2 with
total mortality and CVD events were attenuated and no
longer statistically signiﬁcant in models including mutual
adjustment for other TFAs (Figure 3). In contrast, even with
these exclusions, t/t-18:2 remained associated with higher
risk of total mortality and CVD outcomes in multivariable-
adjusted models that were not mutually adjusted for all
TFAs.
Discussion
In this large, prospective study of older Americans, we found
divergent associations of different circulating TFA subtypes
with total mortality, CVD mortality, and incident CHD. t/t-18:2
appeared most strongly associated with higher risk of total
mortality, CVD mortality, and total CHD. t/c-18:2 was also
positively associated with risk, but primarily only after mutual
adjustment for all TFAs. In contrast, t-16:1n9, t-18:1, and c/t-
18:2 levels were not signiﬁcantly associated with outcomes,
particularly after accounting for reverse causation.
To our knowledge, no prior study has evaluated how
different t-18:2 isomers relate to mortality or incident CHD.
Prior studies, including from this cohort, have found that
total t-18:2 relates to higher risk of fatal ischemic heart
disease (IHD),18 sudden cardiac arrest,19 total42 and nonfatal
CHD,22 possibly related to adverse lipid effects,43 pro-
inﬂammatory responses,9,10 and abnormal heart rate vari-
ability.44 Our sensitivity analysis investigating total t-18:2
also found a positive association with total mortality. Yet, our
isomer-speciﬁc analyses demonstrated substantial heteroge-
neity in associations of each t-18:2 isomers with mortality
and CHD, with most pronounced adverse associations for t/
t-18:2. Based on in vitro studies of human endothelial cells,
t/t-18:2 has multiple adverse effects: increasing NF-кB,
impairing endothelial insulin signaling and NO production,
elevating superoxide production,45 inducing apoptosis and
necrosis in a dose- and time-dependent fashion.46 Yet, these
studies did not compare effects of other t-18:2 isomers. In
addition, animal studies indicate that t/t-18:2 is preferen-
tially incorporated into sn-1 position of phospholipids, similar
to saturated fatty acids, whereas mono t-18:2 isomers such
as c/t- or t/c-18:2 were acylated into sn-2 position, similar
to linoleic acid.47,48 The fundamental biological differences
may result in varying cardiovascular effects of t-18:2, as
Table 4. Prospective Association of Plasma Phospholipid Trans–Fatty Acid With Cardiovascular and Noncardiovascular Mortality
With Mutual Adjustment (n=2742)
Quintiles of Plasma Phospholipid Trans–Fatty Acid Levels
P Value For
Trend*I II III IV V
Cardiovascular mortality (n=567)
Trans16:1n9 1.00 (ref) 1.37 (1.04, 1.80) 1.21 (0.89, 1.65) 1.16 (0.82, 1.63) 1.20 (0.81, 1.76) 0.65
Total trans18: 1† 1.00 (ref) 0.72 (0.54, 0.96) 0.64 (0.46, 0.89) 0.71 (0.48, 1.04) 0.66 (0.43, 1.01) 0.14
Cis/trans18:2 1.00 (ref) 0.75 (0.57, 1.00) 0.74 (0.54, 1.02) 0.87 (0.61, 1.24) 0.81 (0.53, 1.23) 0.43
Trans/cis18:2 1.00 (ref) 1.02 (0.77, 1.34) 1.02 (0.74, 1.39) 1.12 (0.80, 1.57) 1.15 (0.78, 1.70) 0.40
Trans/trans18:2 1.00 (ref) 1.17 (0.89, 1.54) 1.18 (0.89, 1.55) 1.25 (0.95, 1.66) 1.40 (1.05, 1.86) 0.02
Noncardiovascular disease mortality (n=1166)
Trans16:1n9 1.00 (ref) 0.91 (0.75, 1.11) 0.99 (0.80, 1.22) 0.83 (0.66, 1.05) 0.98 (0.76, 1.28) 0.86
Total trans18:1† 1.00 (ref) 0.90 (0.73, 1.11) 0.90 (0.71, 1.14) 1.03 (0.79, 1.35) 0.93 (0.68, 1.26) 0.91
Cis/trans18:2 1.00 (ref) 0.95 (0.77, 1.16) 0.93 (0.74, 1.17) 0.93 (0.72, 1.20) 1.00 (0.74, 1.34) 0.94
Trans/cis18:2 1.00 (ref) 0.94 (0.77, 1.15) 1.04 (0.83, 1.29) 1.11 (0.87, 1.41) 1.19 (0.91, 1.56) 0.09
Trans/trans18:2 1.00 (ref) 1.01 (0.83, 1.21) 1.04 (0.86, 1.25) 1.02 (0.85, 1.24) 1.16 (0.96, 1.42) 0.14
Models were adjusted for age (years), sex (male/female), race (white/nonwhite), education (<high school, high school, some college, college graduate), enrollment site, diabetes (yes/no),
hypertension (yes/no), smoking (never/former/current), alcohol consumption (servings/week), physical activity (kcal/week), BMI (kg/m2), waist circumference (cm), dietary saturated fat
(%energy), dietary monounsaturated fat (%energy), dietary ﬁber (g/day), plasma phospholipid EPA+DHA (% fatty acids), plasma phospholipid linoleic acid (% fatty acids), and other types of
plasma phospholipid trans–fatty acids (% of fatty acids). BMI indicates body–mass index; EPA+DHA, eicosapentaenoic acids plus docosahexaenoic acids.
*P-trend was evaluated by assigning each participant the median value of each quintile category and evaluating this as a continuous variable.
†Total trans18:1 consisted of subtypes including trans-18:1n6, n7, n8, n9, n10-12 that were highly inter-related (pairwise correlations=0.83 to 0.93).
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suggested in our study. Together with our ﬁndings, these
experimental data support adverse cardiovascular effects of
t/t-18:2.
t/c-18:2 was positively associated with total and nonfatal
CHD after mutual adjustment for other TFAs. Because various
TFA subtypes and isomers (in particular t/c- and c/t-18:2)
may be causally intercorrelated due to common dietary
sources, the ﬁndings following mutual adjustment should be
interpreted cautiously. For example, our prior work in CHS
showed that fried and bakery foods are common food sources
of both c/t- and t/c-18:2.17 Whether the signiﬁcant associ-
ations of t/c-18:2 with CHD represent a true effect or an
artifact of overadjustment in this cohort is not known. Of
note, combined levels of t/c- and c/t-18:2 have been shown
to be associated with sudden cardiac arrest in this cohort.19
Unexpectedly, we observed c/t-18:2 to be inversely
associated with incidence of total and nonfatal CHD. Yet,
these inverse associations were attenuated and no longer
statistically signiﬁcant after we excluded cases occurring in
the ﬁrst 2 years. Because the excluded cases were not
younger than participants having events later in the follow-up,
this result could not be interpreted as a stronger association
of c/t-18:2 with premature CHD events. Instead, the ﬁndings
suggested the possibility of reverse causation (ie, participants
with substantial undiagnosed disease might have adapted
healthier dietary habits or such disease could alter phospho-
lipid c/t-18:2 levels). However, excluding earlier cases also
hindered our ability to incorporate the short-term effects of c/
t-18:2 on CHD incidence into the ﬁnal estimates, which could
partially explain the attenuation of the association. Our
interpretation of the ﬁndings after excluding earlier cases
could be speculative, and additional investigation of the
biologic effects of c/t-18:2 are needed to conﬁrm our
ﬁndings.
Neither total t-18:1 nor t-16:1n9 were signiﬁcantly asso-
ciated with total mortality, CVD mortality, or CHD. These
ﬁndings are consistent with prior biomarker studies showing
no signiﬁcant associations of erythrocyte membrane or
Table 5. Prospective Association of Plasma Phospholipid Trans–Fatty Acid With Total Coronary Heart Disease With Mutual
Adjustment (n=2742)
Quintiles of Plasma Phospholipid Trans–Fatty Acid Levels
P Value For
Trend*I II III IV V
Total coronary heart disease (n=639)
Trans16:1n9 1.00 (ref) 1.26 (0.96, 1.64) 1.35 (1.01, 1.80) 1.36 (0.99, 1.87) 1.30 (0.90, 1.88) 0.22
Total trans18:1† 1.00 (ref) 0.89 (0.68, 1.18) 0.83 (0.61, 1.14) 0.78 (0.54, 1.13) 0.77 (0.51, 1.16) 0.23
Cis/trans18:2 1.00 (ref) 0.63 (0.48, 0.82) 0.57 (0.43, 0.77) 0.53 (0.38, 0.74) 0.50 (0.34, 0.73) 0.001
Trans/cis18:2 1.00 (ref) 1.13 (0.87, 1.48) 1.16 (0.86, 1.56) 1.65 (1.21, 2.25) 1.67 (1.17, 2.40) 0.002
Trans/trans18:2 1.00 (ref) 1.14 (0.88, 1.49) 1.43 (1.11, 1.85) 1.40 (1.07, 1.81) 1.39 (1.06, 1.83) 0.01
Coronary heart disease mortality (n=362)††
Trans16:1n9 1.00 (ref) 1.28 (0.91, 1.81) 1.26 (0.86, 1.85) 1.20 (0.79, 1.83) 1.17 (0.71, 1.91) 0.68
Total trans18:1† 1.00 (ref) 0.70 (0.49, 1.00) 0.65 (0.43, 0.96) 0.60 (0.37, 0.98) 0.65 (0.38, 1.13) 0.20
Cis/trans18:2 1.00 (ref) 0.85 (0.61, 1.20) 0.75 (0.50, 1.11) 0.75 (0.48, 1.18) 0.64 (0.38, 1.08) 0.10
Trans/cis18:2 1.00 (ref) 0.92 (0.65, 1.31) 0.89 (0.60, 1.32) 1.32 (0.88, 1.98) 1.38 (0.86, 2.23) 0.07
Trans/trans18:2 1.00 (ref) 1.23 (0.87, 1.74) 1.30 (0.91, 1.84) 1.36 (0.96, 1.93) 1.36 (0.94, 1.96) 0.11
Nonfatal coronary heart disease (n=377)††
Trans16:1n9 1.00 (ref) 1.36 (0.94, 1.96) 1.72 (1.17, 2.54) 1.61 (1.05, 2.47) 1.68 (1.03, 2.73) 0.06
Total trans18:1† 1.00 (ref) 1.09 (0.74, 1.59) 1.15 (0.76, 1.74) 1.00 (0.61, 1.61) 0.97 (0.56, 1.66) 0.72
Cis/trans18:2 1.00 (ref) 0.47 (0.33, 0.66) 0.44 (0.30, 0.64) 0.38 (0.25, 0.58) 0.35 (0.21, 0.56) <0.001
Trans/cis18:2 1.00 (ref) 1.37 (0.96, 1.95) 1.52 (1.03, 2.24) 2.11 (1.41, 3.16) 2.06 (1.29, 3.28) 0.002
Trans/trans18:2 1.00 (ref) 1.10 (0.77, 1.56) 1.40 (1.00, 1.95) 1.29 (0.92, 1.82) 1.36 (0.95, 1.95) 0.08
Models were adjusted for age (years), sex (male/female), race (white/nonwhite), education (<high school, high school, some college, college graduate), enrollment site, diabetes (yes/no),
hypertension (yes/no), smoking (never/former/current), alcohol consumption (servings/week), physical activity (kcal/week), BMI (kg/m2), waist circumference (cm), dietary saturated fat
(%energy), dietary monounsaturated fat (%energy), dietary ﬁber (g/day), plasma phospholipid EPA+DHA (% fatty acids), plasma phospholipid linoleic acid (% fatty acids), and other types of
plasma phospholipid trans fatty acids (% of fatty acids). BMI indicates body–mass index; EPA+DHA, eicosapentaenoic acids plus docosahexaenoic acids.
*P-trend was evaluated by assigning each participant the median value of each quintile category and evaluating this as a continuous variable.
†Total trans18:1 consisted of subtypes including trans-18:1n6, n7, n8, n9, n10-12 that were highly inter-related (pairwise correlations=0.83 to 0.93).
††Subtypes of total coronary heart disease.
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adipose t-18:1 levels with risk of sudden cardiac arrest or
nonfatal CHD.19,20,22 In a prior nested case–control study in
CHS, we found an inverse association between plasma
phospholipid t-18:1 and fatal CHD;18 this was no longer
signiﬁcant in this present analysis with more cases and longer
follow-up time. Animal experiments suggest different t-18:1
isomers could have opposing inﬂuences on risk;45,49–52
therefore, effects may be masked when their sums are
evaluated. Yet, t-18:1 isomers were highly intercorrelated in
our cohort, precluding their separate evaluation.
The absence of association between circulating t-18:1 and
CVD outcomes is puzzling, given that this fatty acid is the
major contributor to total TFA consumption from PHVO, which
has been consistently linked to adverse lipid effects in
trials,4,53 and elevated CHD risk when estimated from
self-reported dietary questionnaires.53 This lack of association
could be attributable, at least partly, to a survival effect, in
that this cohort included elderly individuals who may already
have survived higher exposure to TFA due to other charac-
teristics protecting them from adverse outcomes. In addition,
although t-18:1 is the major component of total TFA from
PHVO, the correlation between circulating and dietary t-18:1
was low (r=0.16) in this cohort, consistent with the not high
correlation between plasma and dietary TFAs in the Nurses’
Health Study (r=0.30).54 Circulating t-18:1 levels reﬂect not
only the dietary intake, but also the yet unknown incorpora-
tion and metabolic processes that may result in different
associations for circulating versus dietary TFAs. On the other
hand, blood levels of dietary fatty acids generally provide
more reliable estimates than self-reported intakes. The overall
low laboratory coefﬁcients of variation and the reasonable
reliability of the exposures indicate the overall good mea-
surements of circulating TFAs, despite the difﬁculty in
quantifying TFAs with small peaks. Our results highlight the
need to further investigate the determinants of t-18:1
biomarker levels and to conﬁrm their relations to disease
risk and the related mechanisms.
Our study has important public health implications. We
identiﬁed positive associations of t/c- and t/t-18:2 with
mortality and CVD. These results provide support for the
recent US Food and Drug Administration proposal to remove
PHVO from the list of additives that are generally recognized
as safe.1 In addition, the speciﬁc associations of these t-18:2
isomers with risks call attention to potential additional
priorities for food policy. The recent US Food and Drug
Administration proposal,1 current food labeling laws,55 and
state and national regulations56,57 are all focused on PHVO
and based on total TFA, which is predominantly t-18:1 and
t-16:1n9. Yet, c/t- and t/c-18:2 can be produced via
processes unrelated to partial hydrogenation, such as
vegetable oil deodorization and high-temperature frying.58–60
If t-18:2 isomers are especially harmful for CVD, even at low
Table 6. Prospective Association of Plasma Phospholipid Trans–Fatty Acid With Cardiovascular and Noncardiovascular Mortality
Without Mutual Adjustment (n=2742)
Quintiles of Plasma Phospholipid Trans–Fatty Acid Levels
P Value For
Trend*I II III IV V
Cardiovascular mortality (n=567)
Trans16:1n9 1.00 (ref) 1.22 (0.94, 1.59) 1.01 (0.77, 1.32) 0.94 (0.71, 1.25) 0.98 (0.74, 1.30) 0.36
Total trans18:1† 1.00 (ref) 0.75 (0.58, 0.97) 0.67 (0.51, 0.87) 0.75 (0.57, 0.99) 0.73 (0.55, 0.96) 0.08
Cis/trans18:2 1.00 (ref) 0.70 (0.54, 0.90) 0.66 (0.50, 0.86) 0.78 (0.60, 1.01) 0.75 (0.56, 0.98) 0.12
Trans/cis18:2 1.00 (ref) 0.86 (0.67, 1.11) 0.81 (0.62, 1.06) 0.91 (0.70, 1.19) 0.90 (0.69, 1.18) 0.74
Trans/trans18:2 1.00 (ref) 1.14 (0.87, 1.50) 1.15 (0.88, 1.51) 1.22 (0.93, 1.60) 1.35 (1.02, 1.77) 0.03
Noncardiovascular disease mortality (n=1166)
Trans16:1n9 1.00 (ref) 0.91 (0.75, 1.09) 0.98 (0.82, 1.18) 0.86 (0.71, 1.05) 1.05 (0.87, 1.26) 0.62
Total trans18:1† 1.00 (ref) 0.89 (0.73, 1.07) 0.89 (0.74, 1.08) 1.04 (0.86, 1.26) 1.01 (0.83, 1.24) 0.36
Cis/trans18:2 1.00 (ref) 0.92 (0.77, 1.12) 0.95 (0.78, 1.14) 0.99 (0.82, 1.20) 1.13 (0.93, 1.38) 0.12
Trans/cis18:2 1.00 (ref) 0.91 (0.75, 1.09) 0.98 (0.81, 1.18) 1.06 (0.88, 1.28) 1.17 (0.97, 1.41) 0.02
Trans/trans18:2 1.00 (ref) 0.99 (0.82, 1.19) 1.03 (0.86, 1.24) 1.03 (0.86, 1.24) 1.16 (0.96, 1.40) 0.12
Models were adjusted for age (years), sex (male/female), race (white/nonwhite), education (<high school, high school, some college, college graduate), enrollment site, diabetes
(yes/no), hypertension (yes/no), smoking (never/former/current), alcohol consumption (servings/week), physical activity (kcal/week), BMI (kg/m2), waist circumference (cm), dietary
saturated fat (%energy), dietary monounsaturated fat (%energy), dietary ﬁber (g/day), plasma phospholipid EPA+DHA (% fatty acids), plasma phospholipid linoleic acid (% fatty acids). BMI
indicates body–mass index; EPA+DHA, eicosapentaenoic acids plus docosahexaenoic acids.
*P-trend was evaluated by assigning each participant the median value of each quintile category and evaluating this as a continuous variable.
†Total trans18:1 consisted of subtypes including trans-18:1n6, n7, n8, n9, n10-12 that were highly interrelated (pairwise correlations=0.83 to 0.93).
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exposure levels such as seen in our study, then current policy
measures may not fully capture all major sources of these
fatty acids. On the global level, while a limited number of
countries such as Denmark,57 Argentina,61 and the United
States1 have national regulations limiting TFAs, the majority of
the world does not. Many countries such as Mexico,62
Egypt,63 and Iran59 still have high consumption of TFAs, with
little active proposed regulation. Other countries such as India
have only proposed but not enforced regulation.64 Our
ﬁndings provide useful insights to inform policy priorities not
only in the United States, but also in these additional
countries. In addition to policy implication, our ﬁndings inform
scientiﬁc knowledge of how different TFA subtypes may
inﬂuence total and cause-speciﬁc mortality, an area that is not
well understood and with many remaining questions. Our
results also highlight the need for further investigation of
dietary determinants, other drivers, and independent disease,
physiologic, and molecular effects of t-18:2 isomers and other
circulating TFA subtypes.
Our study has several strengths. We utilized a well-
established prospective cohort with little loss to follow-up,
minimizing selection bias. TFA levels were assessed using
biomarkers, providing objective measures of exposure and
allowing assessment of individual TFA subtypes and isomers.
Careful follow-up and adjudication of events minimized the
potential for missed or misclassiﬁed outcomes, and the large
number of cases increased statistical power to detect
associations. Information on other risk factors was prospec-
tively collected using standard methods, increasing our
ability to adjust for confounding. We performed several
sensitivity analyses to evaluate the robustness of each
ﬁnding.
Potential limitations deserve consideration. TFA levels
were measured at baseline, and changes in exposure over
time would result in misclassiﬁcation and may attenuate true
associations. We partly accounted for this using regression
dilution correction, but this may incompletely account for
within-person variation over time. Laboratory drift was
Table 7. Prospective Association of Plasma Phospholipid Trans–Fatty Acid With Total Coronary Heart Disease Without Mutual
Adjustment (n=2742)
Quintiles of Plasma Phospholipid Trans–Fatty Acid Levels
P Value For
Trend*I II III IV V
Total coronary heart disease (n=639)
Trans16:1n9 1.00 (ref) 1.17 (0.91, 1.51) 1.24 (0.96, 1.60) 1.18 (0.90, 1.53) 1.06 (0.80, 1.39) 0.92
Total trans18:1† 1.00 (ref) 0.95 (0.74, 1.22) 0.89 (0.69, 1.15) 0.87 (0.66, 1.13) 0.87 (0.67, 1.15) 0.29
Cis/trans18:2 1.00 (ref) 0.65 (0.51, 0.83) 0.64 (0.50, 0.82) 0.66 (0.51, 0.84) 0.67 (0.52, 0.87) 0.01
Trans/cis18:2 1.00 (ref) 0.90 (0.70, 1.15) 0.83 (0.64, 1.07) 1.08 (0.84, 1.38) 1.01 (0.79, 1.30) 0.45
Trans/trans18:2 1.00 (ref) 1.17 (0.90, 1.52) 1.46 (1.14, 1.88) 1.51 (1.17, 1.95) 1.48 (1.13, 1.93) <0.001
Coronary heart disease mortality (n=362)††
Trans16:1n9 1.00 (ref) 1.12 (0.80, 1.56) 1.03 (0.73, 1.44) 0.93 (0.65, 1.32) 0.89 (0.62, 1.28) 0.29
Total trans18:1† 1.00 (ref) 0.73 (0.53, 1.01) 0.69 (0.49, 0.95) 0.64 (0.45, 0.91) 0.69 (0.49, 0.99) 0.06
Cis/trans18:2 1.00 (ref) 0.76 (0.55, 1.03) 0.65 (0.47, 0.91) 0.72 (0.52, 1.00) 0.68 (0.48, 0.97) 0.04
Trans/cis18:2 1.00 (ref) 0.77 (0.56, 1.06) 0.67 (0.48, 0.95) 0.94 (0.68, 1.29) 0.87 (0.62, 1.21) 0.92
Trans/trans18:2 1.00 (ref) 1.20 (0.85, 1.69) 1.23 (0.88, 1.74) 1.36 (0.97, 1.90) 1.33 (0.93, 1.89) 0.10
Nonfatal coronary heart disease (n=377)††
Trans16:1n9 1.00 (ref) 1.37 (0.96, 1.95) 1.78 (1.26, 2.51) 1.59 (1.11, 2.27) 1.46 (1.01, 2.12) 0.09
Total trans18:1† 1.00 (ref) 1.20 (0.86, 1.68) 1.30 (0.93, 1.82) 1.18 (0.82, 1.69) 1.20 (0.83, 1.74) 0.50
Cis/trans18:2 1.00 (ref) 0.57 (0.41, 0.79) 0.64 (0.47, 0.88) 0.63 (0.46, 0.87) 0.64 (0.46, 0.90) 0.03
Trans/cis18:2 1.00 (ref) 1.06 (0.76, 1.47) 1.05 (0.75, 1.46) 1.30 (0.94, 1.80) 1.18 (0.84, 1.66) 0.20
Trans/trans18:2 1.00 (ref) 1.16 (0.82, 1.65) 1.56 (1.12, 2.17) 1.55 (1.11, 2.17) 1.58 (1.12, 2.24) <0.001
Models were adjusted for age (years), sex (male/female), race (white/nonwhite), education (<high school, high school, some college, college graduate), enrollment site, diabetes (yes/no),
hypertension (yes/no), smoking (never/former/current), alcohol consumption (servings/week), physical activity (kcal/week), BMI (kg/m2), waist circumference (cm), dietary saturated fat
(%energy), dietary monounsaturated fat (%energy), dietary ﬁber (g/day), plasma phospholipid EPA+DHA (% fatty acids), plasma phospholipid linoleic acid (% fatty acids). BMI indicates body–
mass index; EPA+DHA, eicosapentaenoic acids plus docosahexaenoic acids.
*P-trend was evaluated by assigning each participant the median value of each quintile category and evaluating this as a continuous variable.
†Total trans18:1 consisted of subtypes including trans-18:1n6, n7, n8, n9, n10-12 that were highly inter-related (pairwise correlations=0.83 to 0.93).
††Subtypes of total coronary heart disease.
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observed for t/t-18:2, possibly related to reduced assay
stability for fatty acids with very low concentrations. In
sensitivity analyses excluding participants with fatty acids
measured in 1999, t/t-18:2 was no longer signiﬁcantly
associated with mortality or CHD after mutual adjustment
for all TFAs, but remained signiﬁcantly positively associated
prior to such mutual adjustment, which would be unrelated
to laboratory drift. In addition, our main analyses corrected
for laboratory drift using calibration, decreasing its inﬂuence
on our ﬁndings. The cohort comprised older, largely white
Americans, and survival bias could partly explain the
absence of associations for t-18:1 and t-16:1n9. Although
the great majority of CVD occurs after age 65, which is the
minimum enrollment age in CHS, the associations of TFA
subtypes may differ in a much younger population.
In conclusion, our ﬁndings suggest that later in life,
circulating t/t-18:2 levels are associated with higher risk of
total mortality, mainly due to increased CVD mortality and
higher risk of total CHD; and t/c-18:2 with higher total
mortality and total CHD. These ﬁndings highlight the
potentially varying health effects of different TFAs, with
implications for both future research and for designing and
evaluating measures to reduce population risk due to TFA
exposures.
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Figure 2. Prospective associations of plasma phospholipid
trans/trans-18:2 with total mortality, CVD and CHD before and
after mutual adjustment without correction of laboratory drift.
Black triangles indicate multivariate-adjusted hazard ratios com-
paring adults in the top quintile category to adults in the bottom
quintile category for t/t-18:2 fatty acid levels, before mutual
adjustment for the 5 TFAs and without correction of laboratory
drift; red diamonds, after mutual adjustment for the 5 TFAs and
without correction of laboratory drift. Error bars represent 95% CI.
All risk estimates were adjusted for age, sex, race, education,
enrollment site, diabetes, hypertension, smoking, alcohol con-
sumption, physical activity, BMI, waist circumference, dietary
saturated fat, dietary monounsaturated fat, dietary ﬁber, plasma
phospholipid EPA+DHA, plasma phospholipid linoleic acid. *P-
trend<0.05 across quintiles. BMI indicates body–mass index;
CHD, coronary heart disease; CVD, cardiovascular disease;
EPA+DHA, EPA+DHA, eicosapentaenoic acids plus docosahexae-
noic acids; TFA, trans–fatty acid.
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Figure 3. Prospective associations of plasma phospholipid
trans/trans-18:2 with total mortality, CVD, and CHD before
and after mutual adjustment after excluding 285 participants
with trans/trans-18:2 levels measured in 1999. Black triangles
indicate multivariate-adjusted hazard ratios comparing adults in
the top quintile category to adults in the bottom quintile
category for t/t-18:2 fatty acid levels, before mutual adjustment
for the 5 TFAs and excluding 285 participants with t/t-18:2
measured early; red diamonds, after mutual adjustment for the 5
TFAs and excluding 285 participants with t/t-18:2 measured
early. Error bars represent 95% CI. All risk estimates were
adjusted for age, sex, race, education, enrollment site, diabetes,
hypertension, smoking, alcohol consumption, physical activity,
BMI, waist circumference, dietary saturated fat, dietary mono-
unsaturated fat, dietary ﬁber, plasma phospholipid EPA+DHA,
plasma phospholipid linoleic acid. *P-trend<0.05 across
quintiles. BMI indicates body–mass index; CHD, coronary
heart disease; CVD, cardiovascular disease; EPA+DHA, eicosa-
pentaenoic acids plus docosahexaenoic acids; TFA, trans–fatty
acid.
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